Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic agent for rhinitis

a technology for rhinitis and rhinitis injection, which is applied in the direction of drug compositions, peptide/protein ingredients, immunological disorders, etc., can solve the problems of reducing the effectiveness of medicine, affecting the effect of rhinitis, and requiring 3 to 4 days of use of such spray preparations, so as to improve rhinorrhea and nasal occlusion, eliminate sneezing and nasal itching, and excellent action

Inactive Publication Date: 2013-02-21
IGISU +1
View PDF3 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a therapeutic preparation for rhinitis that has excellent actions to improve runnelhose, nasal occlusion, and eliminate sneezing and nasal itching. It is fast-acting, not irritating to patients with sensitive nasal mucous membranes, and does not cause any local or systemic side effects. The therapeutic preparation has CNP or BNP as the active ingredient, which is a revolutionary preparation that can relieve symptoms by once-a-day administration. It is effective for any type of rhinitis and has long-lasting drug efficacy. The therapeutic effects are manifested 10 to 20 min after inhalation and the preparation is effective in 100% of the cases. BNP preparations are faster-acting and lead to better improvements in the clinical symptoms than ANP preparations, which is unexpected because they belong to the same family of natriuretic peptide.

Problems solved by technology

However, the use of such spray preparations must be limited to 3 to 4 days.
When used for a longer period than this, the effectiveness of the medicine is reduced and a rebound phenomenon, in which the nasal mucous membranes become more congested than prior to the use, occurs.
In addition, while antihistamine drugs have an effect to suppress runny nose, they also have side effects such as drowsiness.
Disease is usually cured within 10 days, but occasionally bacterial infection occurs, worsening the symptoms and causing a fever.
Discharges inside the nose attach to the wall of the nasal cavity in a crust like manner, releasing a bad odor.
However, the most frequently observed cause is the abuse of a vasoconstrictor nasal drop preparation against nasal occlusion.
As symptoms of atrophic rhinitis (ozena), the nasal mucous membrane becomes thin and hard, and the nasal cavities extend to induce dryness; however, this type of rhinitis is currently rare in Japan.
In any case, rhinitis is a state of the nasal mucous membrane that is swelling by inflammation, characterized by symptoms such as runny nose and stuffy nose, which disturbs the daily lives of patients who experience difficulty in breathing; thus, rhinitis is a troublesome disease.
Effectiveness of antihistamine nasal sprays has been reported, but they are considered to be inferior to steroid nasal sprays.
Meanwhile, steroid nasal sprays elicit some local side effects such as nasal irritation, dryness, burning sensation of the nose, and nasal bleeding.
Furthermore, steroid nasal sprays do not have a long duration of effectiveness, and in the case of adult patients, application of about 4 times a day is necessary.
Furthermore, while antihistamine drugs suppress allergic reactions and their symptoms, they have disadvantages that they cause dryness in the nasal mucous membrane and drowsiness.
Cardiac fibrosis is known to cause diastolic ventricular failure and cardiac dysrhythmia.
However, this literature does not describe any connection between BNP and rhinitis.
However, there is no connection between natriuretic peptides and rhinitis mentioned in this literature.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agent for rhinitis

Examples

Experimental program
Comparison scheme
Effect test

example 1

1. Production of CNP Nasal Solution

[0166]A 1000 μg / ml CNP liquid preparation was prepared by dissolving 3 mg of human CNP-22 (Peptide Institute, Inc.) as the principal agent in 3 ml of saline. 100 μl of the obtained 1000 μg / ml CNP solution preparation was diluted with 900 μl of saline to prepare the CNP nasal solution preparation with a CNP concentration of 100 μg / ml. Similarly, the CNP nasal solution preparation with a CNP concentration of 50 μg / ml was prepared by diluting 50 μl of the 1000 μg / ml CNP solution preparation with 950 μl of saline. Furthermore, similarly, the CNP nasal solution preparation with a CNP concentration of 200 μg / ml was prepared by diluting 200 μl of the 1000 μg / ml CNP solution preparation with 800 μl of saline.

2. Production of Nasal Drop Preparations Consisting of CNP Nasal Solution

[0167]Three kinds of CNP nasal solution preparations with concentrations of 100 μg / ml, 50 μg / ml, and 200 μg / ml obtained as above were used to fill a metered-dose nasal spraying de...

example 2

[0172]Diagnosis, evaluation of symptoms, and examination of the CNP nasal drop preparations, BNP nasal drop preparations and ANP nasal drop preparation were performed as follows.

1. Subjects and Diagnosis

[0173]The subjects are patients in whom conventional external medicines such as steroids are not sufficiently effective, or patients in whom the use of steroids must be avoided due to local side effects such as nasal irritation and dryness. Diagnosis and treatment of these subjects were performed by the present applicant as a medical doctor.

2. Evaluation of Symptoms

[0174]Severity evaluation of symptoms of allergic rhinitis was performed, in principle, in accordance with “Guidelines for medical care of nasal allergies, 2009 edition” (edited by the committee for creation of guidelines for medical care of nasal allergies), by classifying into 5 stages as shown below. Here, “mixed type” refers to the cases wherein both of the sneezing attack or rhinorrhea and the nasal occlusion were pre...

example 3

Diagnosis of Each Case

[0177]Prior to the application of CNP preparations, BNP preparations or ANP preparation, the subjects' history was obtained, scratch tests for allergens were performed and diagnosis was made. Tables 4-7 show the results of the subjects' history taking, diagnosis, i.e., sex, age, past history, family history, scratch test result, diagnostic finding, and symptom evaluation of the subject in each case.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
humidityaaaaaaaaaa
sizeaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The problem to be solved by the present invention is to provide an effective and safe therapeutic preparation for rhinitis, which not only has significant effects on improvement in rhinitis, in particular allergic rhinitis, but also is rapid in manifestation of efficacy, fast-acting, and long-lasting, without local side effects.Means for solving the problem is a therapeutic preparation for rhinitis, in particular allergic rhinitis, comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.

Description

TECHNICAL FIELD[0001]The present invention relates to a therapeutic preparation for rhinitis comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.BACKGROUND ART1. Rhinitis[0002]Rhinitis refers to what is known as an inflammation of the so-called nasal mucous membrane, and histopathologically it is an exudative inflammation, often exhibited as pyogenic inflammation and allergic inflammation. In any cases, it is characterized by exudation of fluid components from the blood vessels, edema, cellular exudates and supersecretion.[0003]Rhinitis includes various types such as acute rhinitis (so-called cold in the nose), chronic rhinitis, and allergic rhinitis depending on the cause and symptoms; usually, it is classified into four types depending on their causes and symptoms, namely infectious rhinitis, hypersensitive non-infectious rhinitis, irritant rhinitis, and others, as shown below.TABLE 11. Infectious(a) Acute rhinitis(b) Chronic rh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/22A61P11/02
CPCA61K38/22A61K38/2242A61P11/00A61P11/02A61P37/08A61K9/0043
Inventor ENDO, KYOKO
Owner IGISU
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com